Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction

Published November 23, 2012

Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction

Filed under: drug treatment news 2012

13, 2012 — /PRNewswire/ — Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it designated the CF602 drug, …
Read more on Sacramento Bee

Report urges move away from prescription drugs to treat chronic pain

Filed under: drug treatment news 2012

A new medical report highlights how Vermont's health care system financially encourages a patient's dependence on opioids, instead of other more effective and less addictive remedies. The report, which was authored by Dr. Cyrus Jordan of the Vermont …
Read more on vtdigger.org

FDA expands Glaxo-Ligand Promacta to hepatitis C patients

Filed under: drug treatment news 2012

The drug, already approved as a treatment for idiopathic thrombocytopenic purpura — low platelet count of unknown cause — was developed along with Ligand Pharmaceuticals Inc. Ligand shares rose as much as 17 percent in heavy volumes by mid-day on …
Read more on Reuters